Clinical Trial

DNA-Repair Defects in Men with Metastatic Prostate Cancer

Study Description

A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer

The purpose of this study is to evaluate the prevalence of 4 or more DNA-repair defects in a population of men with metastatic Prostate Cancer (PC) and to use the variants reported to assess biomarker eligibility for niraparib interventional studies.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Saliva, Blood, or Existing Tissue Sample Collection and Analysis

Saliva or blood sample (or both) or existing tissue sample analysis will be collected from the participants with metastatic PC for genetic testing to determine if DNA-repair defects are present.

Additional Information

Official Study Title

Biomarker Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer

Clinical Trial ID

NCT03871816

ParticipAid ID

bDkx5a